Frank Wolf

Frank Wolf

Auto-generated profile, based on publicly available information

Frank Wolf

Department of Radiation Oncology, Paracelsus Medical University of Salzburg, Salzburg, Austria

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2019 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
ASAndreas Schörghofer
Andreas Schörghofer
MDMartin Drerup
Martin Drerup
TKThomas Kunit
Thomas Kunit
Lukas LusuardiLukas Lusuardi
Lukas Lusuardi
JHJosef Holzinger
Josef Holzinger
FWFrank Wolf
Frank Wolf
Rectal spacers are used to limit dose to the anterior rectal wall in high dose external beam radiation therapy of the prostate and have been shown to reduce radiation induced toxicity. Here we report the complication rate and toxicity of the implantation procedure in a large cohort of patients who have either received a gel- or balloon-type spacer. In total, 403 patients received rectal spacing, 264 with balloon, 139 with gel. Allocation was non-randomized. Two hundred seventy-six patients were treated with normofractionated regimen, the remaining 125 patients in moderate hypofractionation. Spacer related acute and late rectal toxicity was prospectively assessed by endoscopy using a mucosa scoring system (Vienna Rectoscopy Score) as well as CTCAE V.4. For the balloon subgroup, position and rotation of balloon spacers were additionally correlated to incidence and grade of rectal reactions in a post-hoc analysis of post-implant planning MRIs. Overall rectal toxicity was very low with average VRS scores of 0.06 at the day after implantation, 0.10 at the end of RT, 0.31 at 6 months and 0.42 at 12 months follow up. Acute Grade 3 toxicity (rectum perforation and urethral damage) directly related to the implantation procedure occurred in 1.49% (n = 6) and was seen exclusively in patients who had received the spacer balloon. Analysis of post implant MR imaging did not identify abnormal or mal-rotated positions of this spacer to be a predictive factors for the occurrence of spacer related G3 toxicities. Spacer technology is an effective means to minimize dose to the anterior rectal wall. However, the benefits in terms of dose sparing need to be weighed against the low, but possible risks of complications such as rectum perforation.

1 August 2015 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
FWFrank Wolf
Frank Wolf
CGChristoph Gaisberger
Christoph Gaisberger
IZIngrid Ziegler
Ingrid Ziegler
EKElisabeth Krenn
Elisabeth Krenn
PSPhilipp Scherer
Philipp Scherer
FSFelix Sedlmayer
Felix Sedlmayer

10 December 2020 in Strahlentherapie und Onkologie
Verified
Journal Article
Open access
PDF file
FWFrank Wolf
Frank Wolf
FSFelix Sedlmayer
Felix Sedlmayer
DADaniel Aebersold
Daniel Aebersold
CAClemens Albrecht
Clemens Albrecht
DBDirk Böhmer
Dirk Böhmer
TWThomas Wiegel
Thomas Wiegel
Due to its low fractionation sensitivity, also known as “alpha/beta ratio,” in relation to its surrounding organs at risk, prostate cancer is predestined for hypofractionated radiation schedules assuming an increased therapeutic ratio compared to normofractionated regimens. While moderate hypofractionation (2.2–4 Gy) has been proven to be non-inferior to normal fractionation in several large randomized trials for localized prostate cancer, level I evidence for ultrahypofractionation (>4 Gy) was lacking until recently. An accumulating body of non-randomized evidence has recently been strengthened by the publication of two randomized studies comparing ultrahypofractionation with a normofractionated schedule, i.e., the Scandinavian HYPO-RT trial by Widmark et al. and the first toxicity results of the PACE‑B trial. In this review, we aim to give a brief overview of the current evidence of ultrahypofractionation, make an overall assessment of the level of evidence, and provide recommendations and requirements that should be followed before introducing ultrahypofractionation into routine clinical use.

6 February 2018 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
AEAnn-Katrin Exeli
Ann-Katrin Exeli
DKDaniel Kellner
Daniel Kellner
LELukas Exeli
Lukas Exeli
PSPhil Steininger
Phil Steininger
FWFrank Wolf
Frank Wolf
HDHeinz Deutschmann
Heinz Deutschmann
To date, patients with glioblastoma still have a bad median overall survival rate despite radiation dose-escalation and combined modality treatment. Neurocognitive decline is a crucial adverse event which may be linked to high doses to the cortex. In a planning study, we investigated the impact of dose constraints to the cerebral cortex and its relation to the organs at risk for glioblastoma patients. Cortical sparing was implemented into the optimization process for two planning approaches: classical intensity-modulated radiotherapy (IMRT) and robust treatment planning. The plans with and without objectives for cortex sparing where compared based on dose-volume histograms (DVH) data of the main organs at risk. Additionally the cortex volume above a critical threshold of 28.6 Gy was elaborated. Furthermore, IMRT plans were compared with robust treatment plans regarding potential cortex sparing. Cortical dose constraints result in a statistically significant reduced cerebral cortex volume above 28.6 Gy without negative effects to the surrounding organs at risk independently of the optimization technique. For IMRT we found a mean volume reduction of doses beyond the threshold of 19%, and 16% for robust treatment planning, respectively. Robust plans delivered sharper dose gradients around the target volume in an order of 3 – 6%. Aside from that the integration of cortical sparing into the optimization process has the potential to reduce the dose around the target volume (4 – 8%). We were able to show that dose to the cerebral cortex can be significantly reduced both with robust treatment planning and IMRT while maintaining clinically adequate target coverage and without corrupting any organ at risk. Robust treatment plans delivered more conformal plans compared to IMRT and were superior in regards to cortical sparing.

19 July 2017 in Strahlentherapie und Onkologie
Verified
Journal Article
Open access
PDF file
MGM. Groher
M. Groher
PKP. Kopp
P. Kopp
MDM. Drerup
M. Drerup
HDH. Deutschmann
H. Deutschmann
FSF. Sedlmayer
F. Sedlmayer
FWFrank Wolf
Frank Wolf
Purpose Gold-marker-based image-guided radiation therapy (IGRT) of the prostate allows to correct for inter- and intrafraction motion and therefore to safely reduce margins for the prostate planning target volume (PTV). However, pelvic PTVs, when coadministered in a single plan (registered to gold markers [GM]), require reassessment of the margin concept since prostate movement is independent from the pelvic bony anatomy to which the lymphatics are usually referenced to. Methods We have therefore revisited prostate translational movement relative to the bony anatomy to obtain adequate margins for the pelvic PTVs compensating mismatch resulting from referencing pelvic target volumes to GMs in the prostate. Prostate movement was analyzed in a set of 28 patients (25 fractions each, totaling in 684 fractions) and the required margins calculated for the pelvic PTVs according to Van Herk’s margin formula \(M=2.5\Upsigma +1.64\left (\sigma^{\prime}-\sigma _{p}\right )\). Results The overall mean prostate movement relative to bony anatomy was 0.9 ± 3.1, 0.6 ± 3.4, and 0.0 ± 0.7 mm in anterior/posterior (A/P), inferior/superior (I/S) and left/right (L/R) direction, respectively. Calculated margins to compensate for the resulting mismatch to bony anatomy were 9/9/2 mm in A/P, I/S, and L/R direction and 10/11/6 mm if an additional residual error of 2 mm was assumed. Conclusion GM-based IGRT for pelvic PTVs is feasible if margins are adapted accordingly. Margins could be reduced further if systematic errors which are introduced during the planning CT were eliminated.

28 May 2019 in Strahlentherapie und Onkologie
Verified
Journal Article
Open access
PDF file
ASAndreas Schörghofer
Andreas Schörghofer
MGMichael Groher
Michael Groher
JKJosef Karner
Josef Karner
AKAndrea Kopp
Andrea Kopp
GKGerhard Kametriser
Gerhard Kametriser
FWFrank Wolf
Frank Wolf
Prostate cancer (PCA) is highly heterogeneous in terms of its oncologic outcome. We therefore aimed to tailor radiation treatment to the risk status by using three different hypofractionated radiation regimen differing in applied dose, use of rectum spacer, inclusion of pelvic lymph nodes (pLN) and use of androgen deprivation therapy (ADT). Here we report on acute toxicity, quality of life (QOL) and oncologic outcome at a median follow-up of 12 months.